

Resource Summary Report

Generated by [dkNET](#) on Aug 5, 2026

Recombinant Anti-MelanA antibody [EPR20380]

RRID:AB_2889292

Type: Antibody

Proper Citation

Abcam Cat# ab210546, RRID:AB_2889292

Antibody Information

URL: http://antibodyregistry.org/AB_2889292

Proper Citation: Abcam Cat# ab210546, RRID:AB_2889292

Target Antigen: MelanA

Clonality: recombinant monoclonal

Antibody Name: Recombinant Anti-MelanA antibody [EPR20380]

Description: This recombinant monoclonal targets MelanA

Clone ID: EPR20380

Antibody ID: AB_2889292

Vendor: Abcam

Catalog Number: ab210546

Record Creation Time: 20250819T215530+0000

Record Last Update: 20250820T003232+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-MelanA antibody [EPR20380].

No alerts have been found for Recombinant Anti-MelanA antibody [EPR20380].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lucotti S, et al. (2025) Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2. Cell, 188(6), 1642.

Choi YS, et al. (2022) Topical therapy for regression and melanoma prevention of congenital giant nevi. Cell, 185(12), 2071.

Srour N, et al. (2022) PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade. Cell reports, 38(13), 110582.

Rosenbaum SR, et al. (2021) SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects. Cell reports, 37(10), 110085.